Search
Now showing items 1-10 of 10
Drug repositioning in sarcomas and other rare tumors.
(ELSEVIER SCIENCE BV, 2016-03-17)
Proteomic research in sarcomas - current status and future opportunities.
(ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2020-04-01)
Sarcomas are a rare group of mesenchymal cancers comprising over 70 different histological subtypes. For the majority of these diseases, the molecular understanding of the basis of their initiation and progression remains ...
Olaratumab in soft tissue sarcoma - Current status and future perspectives.
(ELSEVIER SCI LTD, 2018-03-01)
Recent randomised phase II trial data have indicated that the addition of olaratumab, a novel monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), to doxorubicin confers an unprecedented ...
The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib.
(TAYLOR & FRANCIS LTD, 2019-10-30)
Introduction: Tyrosine kinases are key mediators of intracellular signaling cascades and aberrations in these proteins have been implicated in driving oncogenesis through the dysregulation of fundamental cellular processes ...
Tropomyosin receptor kinase inhibitors in the management of sarcomas.
(LIPPINCOTT WILLIAMS & WILKINS, 2020-06-05)
PURPOSE OF REVIEW: Genetic aberrations resulting in tropomyosin receptor kinase (TRK) fusion proteins can drive oncogenesis and are postulated to occur in up to 1% of solid tumours. However, TRK fusions in adult sarcomas ...
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry.
(ELSEVIER, 2021-06-15)
Soft tissue sarcomas (STS) are a group of rare and heterogeneous cancers. While large-scale genomic and epigenomic profiling of STS have been undertaken, proteomic analysis has thus far been limited. Here we utilise ...
Phase III Soft Tissue Sarcoma Trials: Success or Failure?
(SPRINGER, 2017-03-01)
Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II ...
Endosialin expression in soft tissue sarcoma as a potential marker of undifferentiated mesenchymal cells.
(NATURE PUBLISHING GROUP, 2016-08-09)
BACKGROUND: Soft tissue sarcomas are a group of neoplasms with differentiation towards mesenchymal tissue, many of which are aggressive and chemotherapy resistant. Histology and immunoprofiles often overlap with neoplasms ...
The biology and treatment of leiomyosarcomas.
(ELSEVIER SCIENCE INC, 2023-04-01)
Leiomyosarcoma (LMS) is a soft tissue sarcoma of smooth muscle origin that can arise in multiple anatomical sites and is broadly classified as extra-uterine LMS or uterine LMS. There is substantial interpatient heterogeneity ...
Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas.
(SPRINGER, 2022-02-16)
Advances in proteomic and metabolomic technologies have accelerated our understanding of multiple aspects of cancer biology across distinct tumour types. Here we review the current state-of-the-art in the use of proteomics ...